Robert Michael Dudley, Chief Executive Officer at Transcode Therapeutics, Inc. (RNAZ), bought 30,000 shares at $1.84 ($55K) on 2022-05-27, disclosed to the SEC on 2022-06-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.84 | 28,000 | $52K | 93.2% |
| 2 | $1.87 | 2,000 | $4K | 6.8% |
| Total | $1.84 avg | 30,000 | $55K | 100% |
| Filing → |
| RNAZ | BUY | 2023-06-14 | $105K | — | Filing → |
| RNAZ | BUY | 2022-09-16 | $23K | — | Filing → |